Practical Management of Adverse Events Associated With FGFR Inhibitors for Cholangiocarcinoma for the Advanced...

Area of Science:

• Oncology
• Pharmacology

Background:

• Cholangiocarcinoma (bile duct cancer) often presents late with a poor prognosis.
• Selective fibroblast growth factor receptor (FGFR) inhibitors show efficacy for cholangiocarcinoma with FGFR2 alterations.
• These inhibitors cause adverse events (AEs) like hyperphosphatemia, fatigue, and GI/ocular/dermatologic issues.

Purpose of the Study:

• To provide advanced practice providers (APPs) with practical insights for managing common AEs of selective FGFR inhibitors.
• To focus on real-world management strategies for pemigatinib and futibatinib.
• To discuss impacts of patient-specific factors and interactions on AE management.

Main Methods:

• Review of current literature and clinical practice guidelines.
• Focus on common AEs associated with pemigatinib and futibatinib.
• Discussion of management strategies, including prophylaxis and supportive care.

Main Results:

• Anticipating and managing AEs improves treatment adherence and patient outcomes.
• Multidisciplinary care involving APPs is essential.
• Practical recommendations for managing specific AEs are provided.

Conclusions:

• Effective management of AEs associated with FGFR inhibitors is key for cholangiocarcinoma treatment.
• APPs play a vital role in optimizing patient care and outcomes.
• This review serves as a resource for healthcare professionals and patients.